Titre : Facteurs d'épissage des ARN

Facteurs d'épissage des ARN : Questions médicales fréquentes

Termes MeSH sélectionnés :

Randomized Controlled Trials as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Facteurs d'épissage des ARN : Questions médicales les plus fréquentes", "headline": "Facteurs d'épissage des ARN : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Facteurs d'épissage des ARN : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-05-12", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Facteurs d'épissage des ARN" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines de liaison à l'ARN", "url": "https://questionsmedicales.fr/mesh/D016601", "about": { "@type": "MedicalCondition", "name": "Protéines de liaison à l'ARN", "code": { "@type": "MedicalCode", "code": "D016601", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine PTB", "alternateName": "Polypyrimidine Tract-Binding Protein", "url": "https://questionsmedicales.fr/mesh/D038941", "about": { "@type": "MedicalCondition", "name": "Protéine PTB", "code": { "@type": "MedicalCode", "code": "D038941", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.250" } } }, { "@type": "MedicalWebPage", "name": "Facteur d'épissage associé à PTB", "alternateName": "PTB-Associated Splicing Factor", "url": "https://questionsmedicales.fr/mesh/D000072670", "about": { "@type": "MedicalCondition", "name": "Facteur d'épissage associé à PTB", "code": { "@type": "MedicalCode", "code": "D000072670", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.282" } } }, { "@type": "MedicalWebPage", "name": "Petites ribonucléoprotéines nucléaires U1", "alternateName": "Ribonucleoprotein, U1 Small Nuclear", "url": "https://questionsmedicales.fr/mesh/D017412", "about": { "@type": "MedicalCondition", "name": "Petites ribonucléoprotéines nucléaires U1", "code": { "@type": "MedicalCode", "code": "D017412", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.313" } } }, { "@type": "MedicalWebPage", "name": "Petites ribonucléoprotéines nucléaires U2", "alternateName": "Ribonucleoprotein, U2 Small Nuclear", "url": "https://questionsmedicales.fr/mesh/D017413", "about": { "@type": "MedicalCondition", "name": "Petites ribonucléoprotéines nucléaires U2", "code": { "@type": "MedicalCode", "code": "D017413", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.344" } } }, { "@type": "MedicalWebPage", "name": "Petites particules nucléaires ribonucléoprotéiques U5", "alternateName": "Ribonucleoprotein, U5 Small Nuclear", "url": "https://questionsmedicales.fr/mesh/D017415", "about": { "@type": "MedicalCondition", "name": "Petites particules nucléaires ribonucléoprotéiques U5", "code": { "@type": "MedicalCode", "code": "D017415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.375" } } }, { "@type": "MedicalWebPage", "name": "Facteurs d'épissage riches en sérine-arginine", "alternateName": "Serine-Arginine Splicing Factors", "url": "https://questionsmedicales.fr/mesh/D000068103", "about": { "@type": "MedicalCondition", "name": "Facteurs d'épissage riches en sérine-arginine", "code": { "@type": "MedicalCode", "code": "D000068103", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.500" } } }, { "@type": "MedicalWebPage", "name": "Facteur d'épissage U2AF", "alternateName": "Splicing Factor U2AF", "url": "https://questionsmedicales.fr/mesh/D000072668", "about": { "@type": "MedicalCondition", "name": "Facteur d'épissage U2AF", "code": { "@type": "MedicalCode", "code": "D000072668", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.750" } } }, { "@type": "MedicalWebPage", "name": "Antigène intracellulaire-1 des lymphocytes T", "alternateName": "T-Cell Intracellular Antigen-1", "url": "https://questionsmedicales.fr/mesh/D000074019", "about": { "@type": "MedicalCondition", "name": "Antigène intracellulaire-1 des lymphocytes T", "code": { "@type": "MedicalCode", "code": "D000074019", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.664.962.829.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Facteurs d'épissage des ARN", "alternateName": "RNA Splicing Factors", "code": { "@type": "MedicalCode", "code": "D000072260", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Omar Abdel-Wahab", "url": "https://questionsmedicales.fr/author/Omar%20Abdel-Wahab", "affiliation": { "@type": "Organization", "name": "Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: abdelwao@mskcc.org." } }, { "@type": "Person", "name": "Akihide Yoshimi", "url": "https://questionsmedicales.fr/author/Akihide%20Yoshimi", "affiliation": { "@type": "Organization", "name": "Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. rr2579@cumc.columbia.edu yoshimia@mskcc.org." } }, { "@type": "Person", "name": "Michael Sattler", "url": "https://questionsmedicales.fr/author/Michael%20Sattler", "affiliation": { "@type": "Organization", "name": "Helmholtz Munich, Molecular Targets and Therapeutics Center, Institute of Structural Biology, Ingolstädter Landstrasse 1, 85764, Neuherberg, Germany. michael.sattler@helmholtz-munich.de." } }, { "@type": "Person", "name": "Anke Busch", "url": "https://questionsmedicales.fr/author/Anke%20Busch", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Biology (IMB), 55128 Mainz, Germany." } }, { "@type": "Person", "name": "Kathi Zarnack", "url": "https://questionsmedicales.fr/author/Kathi%20Zarnack", "affiliation": { "@type": "Organization", "name": "Buchmann Institute for Molecular Life Sciences (BMLS), Goethe University Frankfurt, 60438 Frankfurt am Main, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Effectiveness of whole-body electromyostimulation on knee pain and physical function in knee osteoarthritis: a randomized controlled trial.", "datePublished": "2024-09-06", "url": "https://questionsmedicales.fr/article/39242729", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-71552-7" } }, { "@type": "ScholarlyArticle", "name": "Effect of Raloxifene Treatment on Apolipoproteins and Lipoprotein(a) Concentrations in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials.", "datePublished": "2024-08-23", "url": "https://questionsmedicales.fr/article/39181829", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clinthera.2024.07.008" } }, { "@type": "ScholarlyArticle", "name": "Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials.", "datePublished": "2024-08-22", "url": "https://questionsmedicales.fr/article/39172899", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/CORR.0000000000003204" } }, { "@type": "ScholarlyArticle", "name": "Analgesic effectiveness of methoxyflurane inhaler during genicular nerve block in knee osteoarthritis: a randomized controlled trial.", "datePublished": "2024-08-21", "url": "https://questionsmedicales.fr/article/39174051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/rapm-2024-105777" } }, { "@type": "ScholarlyArticle", "name": "Comparing the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock: a randomized controlled trial.", "datePublished": "2024-08-18", "url": "https://questionsmedicales.fr/article/39154316", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00540-024-03383-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Nucléoprotéines", "item": "https://questionsmedicales.fr/mesh/D009698" }, { "@type": "ListItem", "position": 5, "name": "Protéines de liaison à l'ARN", "item": "https://questionsmedicales.fr/mesh/D016601" }, { "@type": "ListItem", "position": 6, "name": "Facteurs d'épissage des ARN", "item": "https://questionsmedicales.fr/mesh/D000072260" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Facteurs d'épissage des ARN - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Facteurs d'épissage des ARN", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Facteurs d'épissage des ARN", "description": "Comment diagnostiquer un trouble d'épissage ?\nQuels examens sont utilisés pour évaluer l'épissage ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux facteurs d'épissage ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles d'épissage ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Facteurs d'épissage des ARN", "description": "Quels sont les symptômes d'un trouble d'épissage ?\nLes troubles d'épissage peuvent-ils causer des cancers ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Facteurs d'épissage des ARN", "description": "Peut-on prévenir les troubles d'épissage ?\nQuels conseils de santé peuvent aider ?\nLes tests prénataux sont-ils utiles ?\nY a-t-il des vaccins pour prévenir ces troubles ?\nComment le conseil génétique aide-t-il ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Facteurs d'épissage des ARN", "description": "Quels traitements sont disponibles pour les troubles d'épissage ?\nLa thérapie génique est-elle efficace ?\nPeut-on utiliser des médicaments pour traiter ces troubles ?\nY a-t-il des essais cliniques en cours ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Facteurs d'épissage des ARN", "description": "Quelles complications peuvent survenir ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Facteurs d'épissage des ARN", "description": "Quels sont les facteurs de risque pour les troubles d'épissage ?\nL'âge est-il un facteur de risque ?\nLes facteurs environnementaux influencent-ils l'épissage ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie influence-t-il les risques ?", "url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un trouble d'épissage ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses d'ARN peuvent identifier des anomalies d'épissage." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'épissage ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'électrophorèse et le séquençage d'ARN sont couramment utilisés pour l'évaluation." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies peuvent être nécessaires pour analyser les tissus affectés." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux facteurs d'épissage ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certains ARN peuvent servir de marqueurs pour ces facteurs." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles d'épissage ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications associées." } }, { "@type": "Question", "name": "Quels sont les symptômes d'un trouble d'épissage ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, incluant fatigue, douleurs musculaires et anomalies neurologiques." } }, { "@type": "Question", "name": "Les troubles d'épissage peuvent-ils causer des cancers ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'épissage sont liées à divers types de cancers." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques comme des convulsions peuvent survenir dans certains cas." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré des anomalies d'épissage." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver progressivement, nécessitant un suivi régulier." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles d'épissage ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques." } }, { "@type": "Question", "name": "Quels conseils de santé peuvent aider ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain et éviter les toxines peut réduire les risques." } }, { "@type": "Question", "name": "Les tests prénataux sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests prénataux peuvent détecter certaines anomalies génétiques liées à l'épissage." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour prévenir ces troubles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles d'épissage." } }, { "@type": "Question", "name": "Comment le conseil génétique aide-t-il ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le conseil génétique informe les familles sur les risques et les options de dépistage." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles d'épissage ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie génique et des médicaments ciblés pour corriger l'épissage." } }, { "@type": "Question", "name": "La thérapie génique est-elle efficace ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle montre des résultats prometteurs, mais son efficacité dépend du type de trouble." } }, { "@type": "Question", "name": "Peut-on utiliser des médicaments pour traiter ces troubles ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent moduler l'épissage et améliorer les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques en cours ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent de nouvelles approches thérapeutiques." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques, des cancers et des maladies métaboliques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent gravement affecter la qualité de vie, nécessitant un soutien médical continu." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent survenir, nécessitant un suivi régulier." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par un traitement précoce et un suivi." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles d'épissage ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles d'épissage sont plus fréquents chez les personnes âgées." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils l'épissage ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut affecter le processus d'épissage des ARN." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire certains risques associés aux troubles d'épissage." } } ] } ] }

Sources (10000 au total)

Effect of Raloxifene Treatment on Apolipoproteins and Lipoprotein(a) Concentrations in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials.

Although various randomized controlled trials (RCTs) have evaluated the effect of raloxifene on apolipoproteins and lipoprotein(a) concentrations in postmenopausal women, the results have been inconsi... Two independent researchers systematically searched the scientific literature (including PubMed/Medline, Scopus, Web of Science, and EMBASE) for English-language randomized controlled trials (RCTs) pu... The present meta-analysis incorporated 12 publications with 14 RCT arms. The comprehensive outcomes derived from the random-effects model revealed a statistically significant increase in ApoA-I (WMD: ... The current meta-analysis of RCTs demonstrates that treatment with raloxifene reduces ApoB and Lp(a) levels while increasing ApoA-I levels in postmenopausal women. Since these effects on lipid compone...

Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials.

For patients with osteoporosis, bisphosphonate therapy can reduce the risk of fractures, but its effect on reducing mortality remains unclear. Previous studies on this topic have produced conflicting ... In a large meta-analysis of placebo-controlled randomized controlled trials (RCTs), we asked: (1) Does bisphosphonate use reduce mortality? (2) Is there a subgroup effect based on whether different bi... We conducted a systematic review using multiple databases, including Embase, Web of Science, Medline (via PubMed), Cochrane Library, and ClinicalTrials.gov, with each database searched up to November ... The use of bisphosphonates did not reduce the overall risk of mortality in patients with osteoporosis (risk ratio 0.95 [95% CI 0.88 to 1.03]). Subgroup analyses involving different bisphosphonate drug... Based on our comprehensive meta-analysis, there is high-quality evidence suggesting that bisphosphonate therapy for patients with osteoporosis does not reduce the overall risk of mortality despite its... Level I, therapeutic study....

Analgesic effectiveness of methoxyflurane inhaler during genicular nerve block in knee osteoarthritis: a randomized controlled trial.

Up to 30% of patients with knee osteoarthritis (KOA) have evidence of sensitization, with a similar proportion experiencing severe pain during procedures. Most patients with KOA are elderly and often ... 42 adults with refractory KOA were randomized into two groups. Methoxyflurane group received a self-titrated methoxyflurane inhaler with local anesthesia whereas lidocaine group received local anesthe... 42 patients with a mean age of 66±12 years participated in this study. There were no significant baseline differences. During the procedure, the methoxyflurane group experienced a significantly greate... A methoxyflurane inhaler combined with local anesthesia provided better procedural pain control than local anesthesia alone with no observable differences in adverse effects. Future studies evaluating...

Comparing the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock: a randomized controlled trial.

Ketamine and fentanyl are commonly used for sedation and induction of anesthesia in critically ill patients. This study aimed to compare the hemodynamic effects of ketamine versus fentanyl bolus in pa... This randomized controlled trial included mechanically ventilated adults with septic shock receiving sedation. Patients were randomized to receive either 1 mg/kg ketamine bolus or 1 mcg/kg fentanyl bo... Eighty-six patients were analyzed. The median (quartiles) delta CO 6 min after drug injection was 71(37, 116)% in the ketamine group versus - 31(- 43, - 12)% in the fentanyl group, P value < 0.001. Th... In patients with septic shock, ketamine bolus was associated with higher CO and SV compared to fentanyl bolus.... Date of registration: 24/07/2023.... gov Identifier: NCT05957302. URL: https://clinicaltrials.gov/study/NCT05957302 ....

Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials.

Tezepelumab has demonstrated its effectiveness in patients with asthma, but its safety, especially for long-term use, needs to be further explored. This systematic review and meta-analysis aimed to de... A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions.... Randomized controlled trials (RCTs) on treatment of asthma with tezepelumab, compared with placebo, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 9... Seven RCTs (enrolling 2050 participants) met the inclusion criteria. Serious adverse event (RR 0.74, 95% CI 0.57 to 0.95), upper respiratory tract infection (RR 0.73, 95% CI 0.55 to 0.96), and asthma ... Long-term (12-52 wk) use of tezepelumab in patients with asthma does not increase the incidence of adverse events....

The effect of perineural dexamethasone on nerve injury and recovery of nerve function after surgery: A randomized controlled trial.

While numerous studies have examined the influence of perineural dexamethasone on nerve block duration, its potential impact on postoperative nerve injury has not been adequately addressed.... This study aims to elucidate the effect of perineural dexamethasone on nerve injury and nerve function recovery after surgery.... A prospective randomized double-blinded trial.... The First Affiliated Hospital of Chengdu Medical College, Chengdu, China. The study was conducted between 14 June and 30 December 2022.... Patients aged 18 - 80 years, ASA I - II, scheduled for elective orthopedic or burn and plastic surgery.... Patients were randomized to receive either perineural dexamethasone (D group) or no dexamethasone (ND group).... Primary outcomes were the incidence and recovery of nerve injury. Secondary outcomes included postoperative pain scores, analgesic consumption, and adverse events.... Initial postoperative nerve injury rates were similar between groups (D: 30.4 %, ND: 33.3 %, P > 0.05). At 12 weeks post-discharge, significantly more patients in the ND group recovered from nerve def... Perineural dexamethasone may impede nerve function recovery, suggesting caution in its use, particularly for patients with pre-existing nerve damage or diabetes. Further research is needed to elucidat... chictr.org.cn, ChiCTR2200059424....